Stocktoria

Bioventus Inc. BVS

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-02-11
Chart by TradingView
8/9
Piotroski F — financial health
0.44
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$568.1M$573.3M$512.3M$512.1M$430.9M
Gross profit$388.2M$388.2M$328.2M$331.1M$302.7M
Operating income$54.0M-$15.2M-$81.7M-$167.2M$12.1M
Net income$22.7M-$36.1M-$156.2M-$158.7M$19.4M
Operating cash flow$74.7M$38.8M$17.5M-$11.4M$23.0M
Free cash flow$72.1M$37.8M$10.2M-$12.9M$9.5M
Total assets$683.6M$728.0M$810.9M$1.4B$1.2B
Total liabilities$455.1M$542.4M$589.8M$960.4M$618.2M
Shareholders' equity$184.1M$185.6M$221.1M$412.2M$607.7M
Ratios
Gross margin68.3%67.7%64.1%64.6%70.3%
Operating margin9.5%-2.7%-16.0%-32.7%2.8%
Net margin4.0%-6.3%-30.5%-31.0%4.5%
FCF margin12.7%6.6%2.0%-2.5%2.2%
Return on assets3.3%-5.0%-19.3%-11.6%1.6%
Return on equity12.3%-19.5%-70.7%-38.5%3.2%
Debt / equity1.52×1.66×1.66×0.93×0.56×
Current ratio1.701.311.530.901.45
Revenue growth-0.9%11.9%0.0%18.8%34.2%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC489,460$4.5M

Why these scores methodology →

Piotroski F-score: 8/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 0.44 (distress)

  • Working capital / assets 0.165
  • Retained earnings / assets -0.49
  • EBIT / assets 0.079
  • Equity / liabilities 0.405

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001665988 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.